Form 4: Entrada Therapeutics Director Gina Chapman Granted 19,000 Stock Options

Entrada Therapeutics, Inc. Director Gina Chapman has been granted 19,000 stock options with an exercise price of $7.90 per share, aligning her interests with shareholder value.

Summary

• Gina Chapman, a Director of Entrada Therapeutics, Inc. (TRDA), was granted 19,000 stock options.
• The transaction date for this grant was June 11, 2025.
• Each option has an exercise price of $7.90.
• The options are for Common Stock, with each option representing the right to buy one share.
• The options will vest and become exercisable on the earlier of the one-year anniversary of June 11, 2025, or the Issuer's next annual meeting of stockholders.
• The options have an expiration date of June 11, 2035.
• Following this transaction, Ms. Chapman beneficially owns 19,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine insider transaction (option grant) which aligns director interests with shareholders, but does not inherently signal significant operational or financial news.

Positives

• The grant of stock options to Director Gina Chapman aligns her financial interests with the long-term performance and shareholder value of Entrada Therapeutics, Inc.
• This is a standard form of compensation for directors, indicating continued commitment and incentivization.

Future Outlook

The granted stock options are subject to a future vesting schedule, becoming exercisable on the earlier of June 11, 2026, or the Issuer's next annual meeting of stockholders, providing a future incentive for the director.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages to align leadership incentives with company performance and shareholder returns.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule (one-year anniversary or next annual meeting) is typical for director equity grants, aiming to retain and incentivize long-term commitment.
• The exercise price being fixed at the grant date's market price (implied by $0 price of derivative and $7.9 exercise price) is standard for incentive stock options.

Stakeholder Impact

• Shareholders: The grant of options to a director helps align the director's interests with shareholder value creation, as the options gain value only if the stock price increases.

Next Steps

• The stock options will vest and become exercisable on the earlier of June 11, 2026, or Entrada Therapeutics' next annual meeting of stockholders.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership